Citadel Advisors’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Citadel Advisors’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,050	Closed	-$103K	–	13282
2025 Q2	$103K	Buy	3,050 +1,900	+165%	+$60.2K	﹤0.01%	11327
2025 Q1	$36.6K	Buy	+1,150	New	+$43.6K	﹤0.01%	12622
2024 Q2	–	Sell	-75	Closed	-$3.41K	–	14698
2024 Q1	$3.41K	Buy	+75	New	+$3.42K	﹤0.01%	13908
2023 Q1	–	Sell	-25	Closed	-$1.26K	–	15002
2022 Q4	$1.26K	Buy	+25	New	+$1.29K	﹤0.01%	14498

Other funds holding GNOM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

OAM

Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

CFD

Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

FIA

Foundations Investment Advisors Phoenix, Arizona $9.72B AUM 29.41% 1-Year Est. Return

Citadel Advisors's GNOM Position: Q2 2026 in Review

Citadel Advisors reduced its Global X Genomics & Biotechnology ETF (GNOM) stake by 0.03% in Q2 2026, selling an estimated $95 and leaving 6,179 shares worth $351K. The position accounts for ﹤0.01% of the portfolio, ranked #10752.

Citadel Advisors first reported a position in GNOM in Q2 2020 and has held it in 11 quarters since. The position peaked at $580K in Q3 2021. 48 funds tracked by Wall St. Rank hold GNOM as of Q2 2026.

Citadel Advisors held 6,179 shares of Global X Genomics & Biotechnology ETF worth $351K as of Q2 2026.
Citadel Advisors sold 2 Global X Genomics & Biotechnology ETF shares in Q2 2026, an estimated $95.
Global X Genomics & Biotechnology ETF made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #10752 holding.
Citadel Advisors first reported a position in Global X Genomics & Biotechnology ETF in Q2 2020 and has held it in 11 quarters since.
Citadel Advisors's Global X Genomics & Biotechnology ETF position peaked at $580K in Q3 2021.
48 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.